samedan logo
 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Mobile-Optimised Continuous Monitoring System from Vaisala Enhances Product Safety

Vaisala Ltd


Vaisala has launched viewLinc 4.0, a new version of its monitoring, alarming and reporting software, which is the heart of the Vaisala Continuous Monitoring System. Aimed at highly demanding controlled and regulated environments in the pharmaceutical and biotechnology industries, the new version offers an optimized mobile interface for remote monitoring and alarm management. This, along with the location-based reporting and data logging capability, allows users to act on alarms immediately, anywhere and anytime on their smart phones, to improve product safety and ensure compliance with GMP and other regulations.

Other key features include a greatly enhanced user interface that is easier to navigate and more customization capabilities in historical reports and live multiple-channel trend display for enhanced reporting. Users can now create reports more quickly in preparation for and during field quality audits.

"We are ecstatic with the Vaisala viewLinc Monitoring System! It not only helps us meet FDA regulatory and accreditation requirements, but we can now monitor multiple sites from any location," states Brad Bayette, Tissue Services Manager at US-based tissue bank.

The improved user interface facilitates easy access to product data in a more familiar Windows-type navigation. In addition, it shows data by location, which allows users to easily find their loggers, swap out devices, and report data by location. With the mobile interface, users can acknowledge and pause alarms, view live trends on any monitored location under their control, and view trend data in real-time.

"Like its predecessors, Vaisala viewLinc 4.0 is easily deployed for monitoring temperature, relative humidity, CO2, differential pressure, level, door switches, and more. But, we built this version of viewLinc based on working closely with viewLinc users. Every new feature and interface capability came from feedback and suggestions we got. viewLinc 4.0 addresses the changing needs of our customers and integrates new technologies and user expectations, such as drag and drop and mobile usage," says Jon Aldous, Product Manager for Vaisala's Life Science business.

Vaisala will offer its customers warranty, software upgrades, technical support and user training services. Language localized versions will be available in May 2012 in French, Chinese, German and Japanese.
phone +44 (0) 121 683 5620
email uksales@vaisala.com
web www.vaisala.com/lifescience
email Bury St Edmunds Office, Unit 2b Hillside Business Park, Kempson Way, Bury St Edmunds, Suffolk, IP32 7EA
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Irvine Scientific Introduces PRIME-XV Mouse Hematopoietic Cell Basal Medium

World leader in the manufacture of cell culture media announces its new product for the research market
More info >>


White Papers

Generating Scientific Insights by Deep Collaboration - Bridging the Big Data Divide Between Clinical and Research

BioFortis

Translational research, biomarker discovery, clinical studies and even biobanking have become increasingly data intensive.  However, generating scientific insights from such disparate “big” data sources across multiple domains is a challenge for both researchers and the informaticians that support them. Download our Deep Collaboration Whitepaper and and learn how to bridge the clinical and research divide to better explore your biomarker based trials.
More info >>

Industry Events

SMi_Paediatric Clinical Trials

20-21 March 2017, Copthorne Tara Hotel, London, UK

SMi is proud to present the return of their 11th annual Paediatric Clinical Trials Conference, 20th – 21st March 2016, London.   Strengthening strategies in paediatric investigation plans remains paramount and with the EMA 10 year review of paediatric regulation a call has been made for greater guidance with the goal of increasing the number of safe paediatric therapeutics on the market.  
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement